Thank you for your interest in Vaccitech and your enquiry about our ongoing clinical trials.
Please note all information on Vaccitech’s clinical trials are posted on https://clinicaltrials.gov/.
Vaccitech is conducting a Phase 1 study to determine the safety and tolerability of different doses of a single dose therapeutic vaccination of ChAdOx1 HBV in healthy participants and in participants with chronic hepatitis B virus (CHB) infection who are virally suppressed with oral antiviral medication. More information and trial site contact details can be found at: https://clinicaltrials.gov/ct2/show/NCT04297917.
General information in regards to Vaccitech can be found on this website.
Following the implementation of GDPR legislation, Vaccitech will not retain any emails which contain personal information and therefore any email communication with Vaccitech will be permanently deleted from our email server.
Get in touch
The Schrodinger Building
The Oxford Science Park
T: +44 01865 818808